Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYPAD: Denosumab and Pembrolizumab in ccRCC
NCT03280667Phase 2Unknown
- Sponsor
- ANZUP Cancer Trials Group
- Start
- Dec 2017
- Primary completion
- Jun 2023
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab, denosumab in clear cell renal cell carcinoma (ccRCC), sponsored by ANZUP Cancer Trials Group. Status: unknown.
02
Drugs
pembrolizumabdenosumab
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT03280667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03280667.